Home / Going-concern warnings / ONCOLYTICS BIOTECH INC
Filed 2026-03-30 路 Form 10-K 路 Accession 0001129928-26-000020 micro
Price before filing: $0.84 (2026-03-27 close, split/dividend-adjusted)
Market cap at flag: $90.4M (2026-03-30) 路 Latest: $59.6M (2026-10-16)
| Window | ONCY | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +3.7% | +12.2% | -8.5% | 2026-04-29 |
| 90 days | +14.5% | +17.2% | -2.7% | 2026-06-29 |
| 180 days | -21.1% | +21.4% | -42.4% | 2026-09-28 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 10 insiders bought $363K (14 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-16 | Seizinger Bernd R. Director | Purchase | 100,000 | $1.04 | $104K | no | Form 4 |
| 2026-02-11 | Aromando Andrew Chief Business Officer | Purchase | 29,600 | $0.86 | $25K | no | Form 4 |
| 2026-02-11 | Kelly Jared Chief Executive Officer, Director | Purchase | 5,600 | $0.84 | $5K | no | Form 4 |
| 2026-02-11 | Seizinger Bernd R. Director | Purchase | 60,000 | $0.83 | $50K | no | Form 4 |
| 2026-02-12 | Andrews Patricia S Director | Purchase | 35,400 | $0.86 | $30K | no | Form 4 |
| 2026-02-12 | Brown Deborah Margaret Director | Purchase | 25,000 | $0.85 | $21K | no | Form 4 |
| 2026-02-12 | Hagerman Allison VP, Product Development | Purchase | 10,000 | $0.83 | $8K | no | Form 4 |
| 2026-02-12 | Heineman Thomas Charles Chief Medical Officer | Purchase | 12,132 | $0.83 | $10K | no | Form 4 |
| 2026-02-12 | Kelly Jared Chief Executive Officer, Director | Purchase | 29,500 | $0.84 | $25K | no | Form 4 |
| 2026-02-12 | Look Kirk Chief Financial Officer | Purchase | 12,000 | $0.84 | $10K | no | Form 4 |
| 2026-02-12 | Pisano Wayne Director | Purchase | 30,000 | $0.84 | $25K | no | Form 4 |
| 2026-02-12 | Seizinger Bernd R. Director | Purchase | 40,000 | $0.85 | $34K | no | Form 4 |
| 2026-03-11 | Parsons James T. Director | Purchase | 10,000 | $1.03 | $10K | no | Form 4 |
| 2026-03-12 | Kelly Jared Chief Executive Officer, Director | Purchase | 5,050 | $0.96 | $5K | no | Form 4 |
| 2026-03-30: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-30 to 2026-04-29. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"These factors raise substantial doubt about our ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-K (period 2025-12-31)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.